Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055250 · ClinicalTrials.gov registry record · Phase 2
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00055250 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 130 participants.
The verdict
NCT00055250, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.
Interventions
- DRUG placebo
- DRUG Gemcitabine
- DRUG LY293111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055250
The ClinicalTrials.gov registry entry for NCT00055250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00055250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055250 about?
NCT00055250 is a clinical study titled "A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer". The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.
What is the current status of trial NCT00055250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2003-01. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00055250?
The interventions under investigation include: placebo (DRUG), Gemcitabine (DRUG), LY293111 (DRUG).
Who is sponsoring clinical trial NCT00055250?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.